Elutia Inc(ELUT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 6:11 PM ET (Korea 9/12 07:11)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.68 | Insider Own | 20.1% | Shs Outstand | 44.3M | Perf Week | -3.57% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 14.29% | Insider Trans | - | Shs Float | 35.4M | Perf Month | -0.98% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.15 | Inst Own | 26.96% | Short Float | 0.05% | Perf Quarter | -15.33% |
| Income | -0.02B | P/S | 2.96 | EPS this Y | -172.41% | Inst Trans | -0.25% | Short Ratio | 0.23 | Perf Half Y | -29.57% |
| Sales | 0.01B | P/B | 2.28 | EPS next 5Y | - | ROA | -57.89% | Short Interest | 0.02M | Perf YTD | 16.93% |
| Book/sh | 0.36 | P/C | 1.8 | EPS past 3/5Y | 30.73% 20.42% | ROE | - | 52W High | -41.52% ($1.38) | Perf Year | -38.17% |
| Cash/sh | 0.45 | P/FCF | - | Sales past 3/5Y | -19.82% -22.04% | ROIC | -128.03% | 52W Low | 62% ($0.50) | Perf 3Y | -35.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -3.02% | Gross Margin | 69.41% | Volatility(W/M) | 12.9% 10.29% | Perf 5Y | -90.99% |
| Dividend TTM | - | EV/Sales | 2.21 | Sales Y/Y TTM | -48.76% | Oper. Margin | -177.07% | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.64 | EPS Q/Q | 32.38% | Profit Margin | -205.11% | RSI (14) | 39.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.77 | Sales Q/Q | -61.25% | SMA20 | -8.99% ($0.89) | Beta | 0.84 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.69 | Earnings | 2026/8/13 | SMA50 | -10.08% ($0.9) | Rel Volume | 0.34 | Prev Close | $0.8 |
| Employees | 26 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | -13.33% -16.31% | SMA200 | -14.25% ($0.94) | Avg Volume(3M) | 0.07M | Price | $0.81 |
| IPO | 2020/10/8 | Option/Short | No/Yes | Trades | 164 | Volume | 25,018 | Change | 1.22% |
Company
ELUT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A regenerative medicine company developing drug-eluting biomaterials designed to prevent infection following medical device implantation. The company sold its BioEnvelope business, which makes protective envelopes for pacemakers and defibrillators, to Boston Scientific for $88 million, and is now focused on developing its next-generation product, NXT-41x.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
ELUT has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -172.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -35.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 27.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $36M.
ELUT $36M PER -
ABT $176B PER 33.0
MDT $116B PER 22.4
SYK $106B PER 28.6
FAQ
What kind of company is ELUT?
ELUT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ELUT?
The market cap of ELUT is approximately $36M, ranking 5,076 within its sector.
What is the 52-week high and low for ELUT?
ELUT has recorded a 52-week high of $1.38 and a low of $0.50.
